Covered recipient · General Payments record
ALEXANDER FISHBERG
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2019–2025
$1,081.54
- Reported across 45 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $531.60 | 17 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $201.41 | 2 |
| Novo Nordisk AS | $100.01 | 4 |
| Phathom Pharmaceuticals, Inc. | $95.92 | 4 |
| ABBVIE INC. | $73.15 | 4 |
| Ardelyx, Inc. | $39.21 | 2 |
| Janssen Biotech, Inc. | $21.90 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.36 | 01/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1201859610 | CMS |
| ABBVIE INC. | $20.66 | 05/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1201859612 | CMS |
| ABBVIE INC. | $15.10 | 08/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1201859614 | CMS |
| ABBVIE INC. | $20.03 | 09/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1201859616 | CMS |
| Ardelyx, Inc. | $15.82 | 10/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247847843 | CMS |
| Ardelyx, Inc. | $23.39 | 10/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247847845 | CMS |
| Janssen Biotech, Inc. | $21.90 | 05/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1175188957 | CMS |
| Lilly USA, LLC | $79.56 | 04/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186496109 | CMS |
| Lilly USA, LLC | $121.85 | 07/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186499665 | CMS |
| Novo Nordisk Inc | $30.46 | 06/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188186170 | CMS |
| Novo Nordisk Inc | $17.66 | 07/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188217055 | CMS |
| Novo Nordisk Inc | $23.87 | 09/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188186540 | CMS |
| Novo Nordisk Inc | $28.02 | 10/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188138938 | CMS |
| Phathom Pharmaceuticals, Inc. | $27.10 | 06/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1219316775 | CMS |
| Phathom Pharmaceuticals, Inc. | $24.33 | 08/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1219261311 | CMS |
| Phathom Pharmaceuticals, Inc. | $21.77 | 10/01/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1219261309 | CMS |
| Phathom Pharmaceuticals, Inc. | $22.72 | 10/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1219261307 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.